Testing NNC0487-0111 Against Placebo in Adults With Heart Failure and Excess Weight
Tests the weekly injection NNC0487-0111 against placebo in adults with heart failure and obesity.
Plain-language title generated from the registry record
Registry title: A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Key facts
- Where
- Actopan, Chihuahua City, Ciudad Madero, Col. Roma Norte, Col. Zona Comercial Plaza Del Sol, Cuauhtémoc, Guadalajara, León, Mérida, Monterrey, Oaxaca City, Querétaro City, San Luis Potosí City, San Nicolás de los Garza, Tlalpan, Torreón, and Xalapa, MexicoSee the 20 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure (class II-IV, stable) and a body mass index of 30 or more. It tests NNC0487-0111 against placebo given by weekly injection.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Heart failure with New York Heart Association class II-IV, in stable condition at screening. People with type 2 diabetes must have been diagnosed at least 30 days before screening.
- Biomarker or test result
- Body Mass Index (BMI) of 30 kg/m^2 or more at screening. HbA1c above 10 % (86 mmol/mol) at screening excludes people.
Main reasons for not taking part
- Heart attack, stroke, unstable angina or worsening heart failure needing hospital stay or intravenous diuretics within 30 days before screening
- Heart failure caused by certain heart muscle, pericardium or valve diseases
- Severe lung disease, such as primary pulmonary hypertension or severe COPD
- History of type 1 diabetes
- Diabetic eye disease treated or expected to need treatment within 180 days
Read by machine on 12 November 2026.
Where in Mexico
- Centro de Atención al Diabético Actopan (CAD)Actopan, MexicoContact: Novo NordiskTaking people
- Centro de Investigación Integral MEDIVESTChihuahua City, MexicoContact: Novo NordiskNot yet recruiting
- SIYODE S.A. de C.V. UnimedenCiudad Madero, MexicoContact: Novo NordiskTaking people
- Clinstile S.A. de C.V.Col. Roma Norte, MexicoContact: Novo NordiskTaking people
- Scientia Investigación Clínica S. C.Col. Zona Comercial Plaza Del Sol, MexicoContact: Novo NordiskTaking people
- Hospital General de México (HGM)Cuauhtémoc, MexicoContact: Novo NordiskNot yet recruiting
- Consultorio Privado Dr Gabriel Arturo RamosGuadalajara, MexicoContact: Novo NordiskNot yet recruiting
- Consultorio Privado Dr. Francisco PadillaGuadalajara, MexicoContact: Novo NordiskTaking people
- Instituto Cardiovascular de León S.C.León, MexicoContact: Novo NordiskTaking people
- Medical Care and Research S.A. de C.V.Mérida, MexicoContact: Novo NordiskTaking people
- Hospital Universitario Dr. José Eleuterio González_MonterreyMonterrey, MexicoContact: Novo NordiskNot yet recruiting
- Hospital Zambrano Hellion TecSaludMonterrey, MexicoContact: Novo NordiskNot yet recruiting
- Internal Medicine Clin TrialsMonterrey, MexicoContact: Novo NordiskNot yet recruiting
- Oaxaca Site Management Organization (OSMO)Oaxaca City, MexicoContact: Novo NordiskNot yet recruiting
- Panamerican Clinical Research Mexico S. A de C.VQuerétaro City, MexicoContact: Novo NordiskNot yet recruiting
- Centro de Atención e Investigación Cardiovascular del Potosi (CICAP)San Luis Potosí City, MexicoContact: Novo NordiskNot yet recruiting
- Centro de Investigación y Control Metabólico S. C.San Nicolás de los Garza, MexicoContact: Novo NordiskTaking people
- Consultorio Dr. Eduardo ChuquiureTlalpan, MexicoContact: Novo NordiskNot yet recruiting
- CIMAB SA de CVTorreón, MexicoContact: Novo NordiskTaking people
- Consultorio 1020 Hospital Angeles XalapaXalapa, MexicoContact: Novo NordiskTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07567001EU 2025-523717-29-00
- Record updated
- 18 August 2026
- Original description
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.Read full original descriptionShow less
Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.
Inclusion: Body Mass Index (BMI) greater than or equal to (>=) 30 kilograms per square metre (kg/m\^2) at screening; Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator; For participants with Type 2 Diabetes (T2D) at screening:; Diagnosed with T2D >= 30 days before screening.
Exclusion: MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization; requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening; Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination; HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree; Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe chronic obstructive pulmonary disease (COPD) defined as:; Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism); Glycaemia-related:; History of type 1 diabetes; Glycated haemoglobin (HbA1c) greater than (>) 10 percent (%) (86 [millimoles per mole] mmol/mol) as measured by local or central laboratory at screening.